RSV is a highly contagious respiratory virus that causes infections of the lungs and breathing passages.1
RSV usually causes mild, cold-like symptoms in healthy adults. However, it can also cause more serious respiratory illnesses and complications, such as infection of the lungs (pneumonia), in older adults and adults with underlying medical conditions.1
Older adults who are at increased risk include those with certain chronic medical conditions, such as chronic lung or heart disease.6
RSV is highly contagious.1
How effective is AREXVY?
In a clinical trial conducted in 17 countries from the northern and southern hemispheres, AREXVY has been shown to have an overall efficacy of 82.6% against RSV-related lower respiratory tract disease.*3 A single dose of Arexvy can help protect against lower respiratory tract disease caused by RSV (RSV-LRTD) for at least two RSV seasons.†3-5
At least 2 RSV seasons.*†3-5
What to expect with AREXVY?
How much is given? 1
Your doctor will give you one single dose of AREXVY as an injection.
How it is given?1
AREXVY is generally injected into a muscle (usually in the upper arm).
What you need to know about receiving the AREXVY vaccine
As with any vaccine, vaccination with AREXVY can have side effects.1,2
AREXVY has benefits and risks – ask your doctor if AREXVY is right for you.
Side effects of AREXVY include1,2: itching, pain, redness or swelling at the injection site, fever, chills, tiredness, headache, muscle pain, joint pain, a runny nose, generally feeling unwell, nausea, stomach pain and swelling of the lymph nodes.
If you need to, ask your doctor or pharmacist if you have any further questions about side effects.1
Do not use AREXVY if you are allergic to AREXVY, or any of its ingredients. Always check the ingredients to make sure you can receive this vaccine. If AREXVY is given at the same time as another vaccine, a different injection site will be used for each injection.1
How much will AREXVY cost?
AREXVY is an unfunded vaccine for individuals 60 years of age and older, and adults 50 through 59 who are at increased risk of RSV disease.7 Please speak to your healthcare professional about expected costs.
…a discussion guide and ask your doctor, nurse or pharmacy about AREXVY and if it’s right for you.
IMPORTANT SAFETY INFORMATION:1,2
You should not be given AREXVY if you are allergic to any of its ingredients. Side effects: headache, muscle pain, joint pain, tiredness and pain at the injection site. This is not a full list. Vaccination with AREXVY may not result in protection of all vaccine recipients. Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you.
*Overall efficacy against RSV-LRTD in people ≥60 years old during one RSV season (AREXVY, 7 cases out of 12,466; placebo 40 cases out of 12,494; median follow-up 6.7 months): 82.6% (96.95% CI: 57.9 to 94.1).2,3 In this study, RSV seasons were defined as from 1 October to 30 April in the northern hemisphere and from 1 March to 30 September in the southern hemisphere.4
†A single dose of AREXVY demonstrated: 67.2% overall efficacy in protecting against RSV-LRTD over two RSV seasons in adults 60 years and older (97.5% CI, 48.2, 80.0); AREXVY (30 cases out of 12,469), placebo (139 cases out of 12,498); median follow-up 17.8 months.5 62.9% overall efficacy in protecting against RSV-LRTD over 3 full RSV seasons in adults aged 60 years and older (97.5% CI, 46.7, 74.8); AREXVY (48 cases out of 12,468), placebo (215 cases out of 12,498); median follow-up 30.6 months.4 In this study, RSV seasons were defined as from 1 October to 30 April in the northern hemisphere and from 1 March to 30 September in the southern hemisphere.4
CI, confidence interval
References:
1. GlaxoSmithKline New Zealand. AREXVY Consumer Medicine Information (CMI). GSK NZ; 2025 Available at https://www.medsafe.govt.nz/consumers/cmi/a/Arexvy.pdf (Accessed February 2026). 2. GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ;2025. Available at https://www.medsafe.govt.nz/profs/datasheet/a/Arexvyinj.pdf (Accessed February 2026). 3. Papi A et al. N Engl J Med 2023;388:595–608. 4. Ison MG;Lancet Respir Med;2025;13(6);517-529. 5. Ison MG;Clinical Infectious Diseases;2024;1-29. 6. CDC;2024;1-5;Clinical Overview of RSV. 7. Health NZ;Immunisation Handbook;2026;1-695
VACCINATION MAY NOT PROTECT ALL RECIPIENTS2
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk of RSV disease. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are allergic to any component of this vaccine. AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor’s charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.